Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

This study has been terminated.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00099879
First received: December 21, 2004
Last updated: February 27, 2010
Last verified: August 2007
  Purpose

The purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC). The safety of this treatment will also be studied.


Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: BMS-275183
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
Official Title: A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced or metastatic pretreated NSCLC
  • Measurable disease
  • Adequate hematologic, hepatic and renal functions
  • ECOG Performance Status of 0-2

Exclusion Criteria:

  • Inability to swallow capsules
  • Recent significant cardiovascular disease
  • Woman who are pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00099879

Locations
United States, California
Local Institution
Sacramento, California, United States
United States, Connecticut
Local Institution
New Haven, Connecticut, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
United States, Illinois
Local Institution
Maywood, Illinois, United States
United States, Michigan
Local Institution
Detroit, Michigan, United States
United States, Pennsylvania
Local Institution
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
Belgium
Local Institution
Brussels, Belgium
Local Institution
Leuven, Belgium
France
Local Institution
Besancon, Cedex, France
Local Institution
Saint-Herblain, Cedex, France
Local Institution
Belfort, France
Italy
Local Institution
Parma, Italy
Local Institution
Roma, Italy
Netherlands
Local Institution
Amsterdam, Netherlands
Local Insitution
Groningen, Netherlands
Spain
Local Institution
Barcelona, Spain
Local Institution
Madrid, Spain
United Kingdom
Local Institution
Shefield, Yorkshire, United Kingdom
Local Institution
Manchester, United Kingdom
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00099879     History of Changes
Other Study ID Numbers: CA165-020
Study First Received: December 21, 2004
Last Updated: February 27, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 28, 2014